Chengdu Origen Biotechnology and Vanotech have begun dosing subjects in the Phase I trial VAN-2401, evaluating KH658 gene therapy for wet AMD. The trial aims to assess safety, tolerability, and efficacy through suprachoroidal space administration.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing